HIV prevention research and COVID-19: putting ethics guidance to the test.


Journal

BMC medical ethics
ISSN: 1472-6939
Titre abrégé: BMC Med Ethics
Pays: England
ID NLM: 101088680

Informations de publication

Date de publication:
25 01 2021
Historique:
received: 14 07 2020
accepted: 14 01 2021
entrez: 26 1 2021
pubmed: 27 1 2021
medline: 5 2 2021
Statut: epublish

Résumé

Critical public health measures implemented to mitigate the spread of the novel coronavirus disease (COVID-19) pandemic have disrupted health research worldwide, including HIV prevention research. While general guidance has been issued for the responsible conduct of research in these challenging circumstances, the contours of the dueling COVID-19 and HIV/AIDS pandemics raise some critical ethical issues for HIV prevention research. In this paper, we use the recently updated HIV Prevention Trials Network (HPTN) Ethics Guidance Document (EGD) to situate and analyze key ethical challenges related to the conduct of HIV prevention research during the COVID-19 pandemic as well as identify potential areas for refinement of the guidance document based on this unprecedented state of affairs. Necessary actions taken for HIV prevention research studies due to the COVID-19 pandemic involve an array of ethical issues including those related to: (1) risk mitigation; (2) behavior change; (3) compounding vulnerability; (4) community engagement; (5) trial reopening; and 6) shifting research priorities. In the context of the dueling HIV and COVID-19 global pandemics, research teams and sponsors must be nimble in responding to the rapidly changing environment by being sensitive to the associated ethical issues. The HTPN EGD provides a rich set of tools to help identify, analyze and address many of these issues. At the same time, future refinements of the HPTN EGD and other research ethics guidance could be strengthened by providing explicit advice regarding the ethical issues associated with disrupted research and the reopening of studies. In addition, additional consideration should be given to appropriately balancing domains of risk (e.g., physical versus social), addressing the vulnerability of research staff and community partners, and responding to un-anticipatable ancillary care needs of participants and communities. Appropriately addressing these issues will necessitate conceptual work, which would benefit from the careful documentation of the actual ethical issues encountered in research, the strategies implemented to overcome them, and their success in doing so. Throughout all of these efforts, it is critical to remember that the HIV pandemic not be forgotten in the rush to deal with the COVID-19 pandemic.

Sections du résumé

BACKGROUND
Critical public health measures implemented to mitigate the spread of the novel coronavirus disease (COVID-19) pandemic have disrupted health research worldwide, including HIV prevention research. While general guidance has been issued for the responsible conduct of research in these challenging circumstances, the contours of the dueling COVID-19 and HIV/AIDS pandemics raise some critical ethical issues for HIV prevention research. In this paper, we use the recently updated HIV Prevention Trials Network (HPTN) Ethics Guidance Document (EGD) to situate and analyze key ethical challenges related to the conduct of HIV prevention research during the COVID-19 pandemic as well as identify potential areas for refinement of the guidance document based on this unprecedented state of affairs.
MAIN BODY
Necessary actions taken for HIV prevention research studies due to the COVID-19 pandemic involve an array of ethical issues including those related to: (1) risk mitigation; (2) behavior change; (3) compounding vulnerability; (4) community engagement; (5) trial reopening; and 6) shifting research priorities.
CONCLUSIONS
In the context of the dueling HIV and COVID-19 global pandemics, research teams and sponsors must be nimble in responding to the rapidly changing environment by being sensitive to the associated ethical issues. The HTPN EGD provides a rich set of tools to help identify, analyze and address many of these issues. At the same time, future refinements of the HPTN EGD and other research ethics guidance could be strengthened by providing explicit advice regarding the ethical issues associated with disrupted research and the reopening of studies. In addition, additional consideration should be given to appropriately balancing domains of risk (e.g., physical versus social), addressing the vulnerability of research staff and community partners, and responding to un-anticipatable ancillary care needs of participants and communities. Appropriately addressing these issues will necessitate conceptual work, which would benefit from the careful documentation of the actual ethical issues encountered in research, the strategies implemented to overcome them, and their success in doing so. Throughout all of these efforts, it is critical to remember that the HIV pandemic not be forgotten in the rush to deal with the COVID-19 pandemic.

Identifiants

pubmed: 33494754
doi: 10.1186/s12910-021-00575-w
pii: 10.1186/s12910-021-00575-w
pmc: PMC7829648
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

6

Subventions

Organisme : NIAID NIH HHS
ID : UM1 AI069456
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068613
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068617
Pays : United States

Références

J Empir Res Hum Res Ethics. 2018 Jul;13(3):239-246
pubmed: 29631486
J Int AIDS Soc. 2020 May;23(5):e25500
pubmed: 32406990
Circulation. 2020 Jun 23;141(25):2045-2047
pubmed: 32320272
Int J Environ Res Public Health. 2020 Jun 24;17(12):
pubmed: 32599783
AIDS Behav. 2020 Aug;24(8):2239-2243
pubmed: 32306214
BMC Med Ethics. 2018 Dec 6;19(1):94
pubmed: 30522485
AIDS Behav. 2020 Aug;24(8):2232-2235
pubmed: 32303924
J Am Geriatr Soc. 2020 Jun;68(6):E14-E18
pubmed: 32315076
Lancet HIV. 2020 Sep;7(9):e629-e640
pubmed: 32771089
AIDS Behav. 2020 Sep;24(9):2486-2489
pubmed: 32347403
Dev World Bioeth. 2013 Aug;13(2):87-94
pubmed: 23725227
AIDS Behav. 2020 Jul;24(7):2009-2012
pubmed: 32415617
AIDS Behav. 2020 Oct;24(10):2748-2750
pubmed: 32356031
AIDS Behav. 2020 Jul;24(7):2024-2032
pubmed: 32350773
Health Equity. 2019 Mar 14;3(1):68-72
pubmed: 31032470

Auteurs

Stuart Rennie (S)

UNC Center for Bioethics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Wairimu Chege (W)

Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.

Leah A Schrumpf (LA)

Family Health International, Durham, NC, USA.

Florencia Luna (F)

FLACSO-Argentina and CONICET, Buenos Aires, Argentina.

Robert Klitzman (R)

Columbia University, New York, NY, USA.

Ernest Moseki (E)

Botswana Harvard AIDS Institute Partnership Princess Marina Hospital, Gaborone, Botswana.

Brandon Brown (B)

Center for Healthy Communities, University of California Riverside School of Medicine, Riverside, CA, USA.

Steven Wakefield (S)

NIAID HIV Vaccine Trials Network, Seattle, WA, USA.

Jeremy Sugarman (J)

Berman Institute of Bioethics, Johns Hopkins University, 1809 Ashland Ave, Baltimore, MD, 21205, USA. jsugarman@jhu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH